

NOVO-NORDISK AS B

ISIN: DK0062498333 WKN: - Asset Class: **Stock**

Company



2024/07/26 17:20:00

Price

873.70

DKK

Difference

-0.90%(-7.90)



Contact Details

NOVO NORDISK A/S Tel: +45-44-44-88-88
 -- Fax: +
 Novo Allé 1 Web: <http://www.novonordisk.com>
 2880 Bagsværd E-mail: -

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	139,646,000,000		108,194,000,000		85,595,000,000	
Common stock capital		451,000,000		456,000,000		462,000,000
Fixed assets	174,840,000,000		133,063,000,000		108,913,000,000	
Equity capital of a company		106,561,000,000		83,486,000,000		70,746,000,000
Cash and cash equivalents	14,392,000,000		12,653,000,000		10,720,000,000	
Accrued liabilities		7,391,000,000		5,352,000,000		5,654,000,000
Other assets	-		-		-	
Current liabilities		169,655,000,000		120,940,000,000		99,516,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		38,270,000,000		36,831,000,000		24,246,000,000
Different income		-		-		-
Other liabilities		189,000,000		100,000,000		360,000,000
Total assets	314,486,000,000	314,486,000,000	241,257,000,000	241,257,000,000	194,508,000,000	194,508,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	63,370	54,393	47,792
Equity ratio	33.88%	34.60%	36.37%
Debt-equity ratio	195.12%	188.98%	174.94%

Others

	2023	2022	2021
Tax Expense Rate	20.07%	19.55%	19.16%

NOVO-NORDISK AS B

ISIN: DK0062498333 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	232,261,000,000	176,954,000,000	140,800,000,000
Net income	83,683,000,000	55,525,000,000	47,757,000,000
EBIT	13,971,242,000	9,322,514,000	7,944,056,000
Operating income before taxes	104,593,000,000	69,251,000,000	59,104,000,000
Cash Flow	108,908,000,000	78,887,000,000	55,004,000,000
Net interest income	330,000,000	-320,000,000	-180,000,000
Research and development expenses	29,373,000,000	21,761,000,000	16,292,000,000
Income taxes	20,991,000,000	13,537,000,000	11,323,000,000
Result from investments in subsidiaries, associates and other	81,000,000	-189,000,000	-24,000,000
Revenues per employee	491,131	435,935	394,777

Board of Directors

Helge Lund	Chairman of Supervisory Board
Martin MacKay	Member of Supervisory Board
Sylvie Grégoire	Member of Supervisory Board
Andreas Fibig	Member of Supervisory Board
Christina Law	Member of Supervisory Board
Elisabeth Christensen	Member of Supervisory Board
Henrik Poulsen	Member of Supervisory Board
Kasim Kutay	Member of Supervisory Board
Laurence Debroux	Member of Supervisory Board
Liselotte Hyveled	Member of Supervisory Board
Mette Bøjer Jensen	Member of Supervisory Board
Thomas Rantzau	Member of Supervisory Board

Members of Management Board

Lars Fruergaard Jørgensen	Chairman of Managing Board
Camilla Sylvest	Member of Executive Committee
David Moore	Member of Executive Committee
Doug Langa	Member of Executive Committee
Henrik Wulff	Member of Executive Committee
Karsten Munk Knudsen	Member of Executive Committee
Ludovic Helfgott	Member of Executive Committee
Marcus Schindler	Member of Executive Committee
Martin Holst Lange	Member of Executive Committee
Maziar Mike Doustdar	Member of Executive Committee
Tania Sabroe	Member of Executive Committee